Leading the way in innovation for over 55 years, we build greater futures for businesses across multiple industries and 55 countries.
Our expert, committed team put our shared values into action – every day. With the best talent and the latest technology we help customers turn complexity into opportunities and create meaningful change.
We share news, insights, analysis and research – tailored to your unique interests – to help you deepen your knowledge and impact.
At TCS, we believe exceptional work begins with hiring, celebrating and nurturing the best people — from all walks of life.
Get access to a catalog of the latest news stories from across TCS. Discover our press releases, reports, and company announcements.
At TCS, we help enterprises grow through innovative solutions globally. Adapt and thrive with us.
You have these already downloaded
We have sent you a copy of the report to your email again.
Tata Consultancy Services’ comprehensive PV services, device complaint management, outcome-based pricing model for AI-led safety operations, and its flagship ADD™ Safety platform, cited as strengths.
NEW YORK | MUMBAI, July 1, 2025: Tata Consultancy Services (TCS) has been positioned as a Leader in Everest Group’s PEAK Matrix® for Pharmacovigilance (PV) Operations services.
The report highlights comprehensive coverage of TCS’ pharmacovigilance services including device complaint management, medical devices product quality complaints, medical device reporting and post market surveillance, as key strengths. TCS’ flagship ADD™ safety platform draws special mention in the report for its touchless processing of individual case safety reports (ICSRs) with in-built quality control, smart signal intelligence, literature surveillance, and safety report authoring.
“The field of pharmacovigilance is experiencing a paradigm shift driven by adoption of AI and technology and a greater emphasis on patient involvement. TCS has been continuously investing in upskilling its associates and developing technology solutions to help its clients achieve speed, quality and compliance in drug safety. Our focus is on proactive risk management by taking an approach which is based on data science-driven predictive decision-making,” said Vikas Jain, Business Head, Life Sciences, TCS. “TCS harnesses its research and development investments to deliver advanced drug and device safety solutions. The company’s PV services are powered by next-gen technologies and offer a transformative experience where intelligent automation assists human intelligence.”
TCS partners with leading life sciences companies and provides end-to-end integrated pharmacovigilance services, including ICSR case processing, signal detection, risk management, local affiliate activities, PV analytics and applications, literature surveillance, aggregate/regulatory reporting, clinical evaluation reports, medical safety assessment, and other pharmacovigilance support activities.
Additionally, TCS offers its proprietary solutions to help life sciences customers accelerate transformation. The TCS ADD™ Safety platform helps automate intake and processing of safety data from structured/unstructured sources. It automates safety case management, uses predictive analytics and signal detection for novel actionable insights.
“As pharmacovigilance becomes more data-intensive and complex, driven by diverse global regulations and increasing demand for real-time safety insights, enterprises are prioritizing partners that offer both platform-driven automation and scalable operations,” said Vandana Sharma, Practice Director, Everest Group. “TCS stands out with its end-to-end pharmacovigilance services, particularly in case processing and product quality complaint management. Its ADD™ Safety platform offers advanced capabilities in predictive signal detection and AI-enabled safety report authoring, and it is evolving toward touchless case processing. TCS’ outcome-based pricing models and active industry engagement reflect a progressive approach to PV modernization. These strengths, underpinned by robust delivery infrastructure and operational excellence, have positioned TCS as a Leader in Everest Group’s Post-Approval Pharmacovigilance PEAK Matrix® Assessment 2025."
Disclaimer: Licensed extracts taken from Everest Group’s PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.